A-052 Antibiotic (AB) activity against Pseudomonas aeruginosa (PA) with Normal or Mucoïd Phenotypes in an Artificial Sputum Medium (ASM) in vitro Biofilm.

Slides:



Advertisements
Similar presentations
A 23 Variability in the Size of the Fluoroquinolone AUC/MIC for Antibacterial Effect in S.aureus: Impact for Clinical Breakpoints A. R. Noel, K.E. Bowker,
Advertisements

Revised Abstract Results Eravacycline (TP-434) is Active In Vitro Against Biofilms Formed by Uropathogenic Escherichia coli W. O’BRIEN, J. SUTCLIFFE, T.
5/20/2015ISAP Is the cellular accumulation of antibiotics a predictive factor for intracellular efficacy ? Sandrine Lemaire Université catholique.
25 MB of information … CONTENT OF THE CD-rom Learning appropriate use of antibiotics (PK/PD and guidelines): a CD-rom course for healthcare professionals.
REVISED ABSTRACT Background: Omadacycline (OMC) is the first of a new class of tetracyclines, the aminomethylcyclines, and is being developed as a once-daily.
Antibiotics Basmah almaarik
Bacterial persistence
Setting-up a model of intracellular infection by Pseudomonas aeruginosa for the pharmacodynamic evaluation of antibiotic activity. J. Buyck1, O. Jolois2,
studies with Caco-2 cells and THP-1 macrophages
Activities of Daptomycin (DAP), Vancomycin (VAN) and Linezolid (LDZ) alone or in combination with Fusidic acid (FUS) in an in vitro dynamic model of.
Activity of tobramycin in combination with clarithromycin
Introduction Results Aim of the study Methods References Conclusion
Comparison of the intracellular and extracellular activities of approved and novel antistaphylococcal antibiotics using a pharmacodynamic model exploring.
In vitro pharmacodynamic models for the study of antibiotic activity against bacterial biofilms Françoise Van Bambeke, PharmD, PhD Pharmacologie cellulaire.
Mix with THP-1 macrophages Overnight bacterial suspension
Frédéric Peyrusson, Françoise Van Bambeke, Paul M. Tulkens
Wafi Siala1,2, Françoise Van Bambeke1 , Thomas Vanzieleghem2
In vitro susceptibility of S
Activity of 9 antibiotics against intracellular forms of S. pneumoniae
P1058 Intracellular activity of antibiotics against a stable small colony variant (SCV) isolated from a CF patient in a model Calu-3 human airway epithelial.
Expression of Efflux system
Revealing moxifloxacin activity against biofilms of S
Can efflux confer high levels resistance to meropenem (MEM) in Pseudomonas aeruginosa (Pa) clinical isolates? H. Chalhoub1, H. Rodriguez-Villalobos2,
Introduction & Purpose Results Conclusions
FUS, VAN and LZD injected twice (T0 and T12); DAP injected once (T0).
This poster will be made available for download after the meeting at :
Epithelial lining fluid penetration of temocillin administered by continuous infusion in critically ill patients with nosocomial pneumonia. Visée C.1a,
Influence of antibiotic treatments on gene expression of RND efflux pumps in successive isolates of Pseudomonas aeruginosa collected from patients with.
Introduction Results Aim Methods References Conclusion
Co-medications Improve Moxifloxacin (MXF) Activity in Models of Pneumococcal Naïve and Induced Biofilms (BF) N. M. Vandevelde1, M. Van Obbergh1, P.M. Tulkens1,
Background and objectives
Comparative in vitro activity of temocillin and other β-lactams
Activity and Pharmacodynamic (PD) Evaluation of Ceftazidime-Avibactam (CAZ-AVI) against Extracellular and Intracellular Forms of CAZ-susceptible and CAZ-resistant.
Inhibitors of type three secretion system [TTSS] protect against Pseudomonas aeruginosa cellular toxicity by inhibiting the transcription of TTSS Mailing.
Mapping French population [1]
Table 2: Percentage of cross resistance among tested antibiotics
Emilien Drouot, Paul M. Tulkens, Françoise Van Bambeke
Julien Buyck, Paul M. Tulkens and Françoise Van Bambeke
Are Vitek2 system and E-test relevant and reliable for determining susceptibility to temocillin? Visée C.1, Frippiat F1, Descy J.2, Meex C.2, Melin P.2,
Julien Buyck, Paul M. Tulkens and Françoise Van Bambeke
Extracellular activity Intracellular activity
Staphylococcus aureus Streptococcus pneumoniae Pseudomonas aeruginosa
Abstract Results Methods Background Conclusions References
cellular accumulation (24h) Cstatic (LZD/RDZ ratio)
Incubation (with antibiotic)
52 - Antimicrobials Radezolid (RX-1741), a Novel Oxazolidinone, Accumulates Extensively within Human Macrophages and PMNs and Shows Activity towards.
Of a Pig-related ST-398 Methicillin-Resistant S. aureus (A-MRSA)
EV0626 Cellular pharmacokinetics of gepotidacin (GSK )
In vitro models for the study of antibiotic PK/PD in biofilms
Abstract Results Aim of the study Methods Background Conclusions
Antibiotic activity of new penams (6-APA) and cephems (7-ACA)
Difference log CFU from time 0
DISCUSSION AND CONCLUSION
INTRODUCTION METHODS CONCLUSIONS REFERENCES
Introduction Results Materials and Methods Conclusions
1200 Brussels - Belgium Temocillin is not substrate for OprD2 porin from Pseudomonas aeruginosa H. Chalhoub1,
Electron microscopy: intracellular infection of THP-1 by S. aureus
Log extracellular concentration (mg/L)
Susceptibility of Pseudomonas aeruginosa (P. a
Activity of Moxifloxacin against Staphylococcus aureus in Models of Persistent Infections (Intracellular Survival, Biofilms) Mailing address: P.M. Tulkens.
M.P. Mingeot-Leclercq, P.M. Tulkens, F. Van Bambeke
Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with.
P1257 Pharmacodynamics of Amikacin Inhale studied in an in vitro pharmacokinetic model of infection KE Bowker, AR Noel, SG Tomaselli, MLG Attwood, AP.
Intracellular models of infection to evaluate antibiotic activity
Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with.
Setting-up of a 24 h model to evaluate the activity of antibiotics against intracellular forms of S. aureus infection C. Seral, M. Barcia-Macay, F. Van.
Dinty J. Musk, David A. Banko, Paul J. Hergenrother 
“Pulmonary infections”
Université catholique de Louvain, Brussels, Belgium
Presentation transcript:

A-052 Antibiotic (AB) activity against Pseudomonas aeruginosa (PA) with Normal or Mucoïd Phenotypes in an Artificial Sputum Medium (ASM) in vitro Biofilm Model E. Bassères, P.M. Tulkens, F. Van Bambeke Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain - Brussels - Belgium Françoise Van Bambeke Pharmacologie cellulaire et moléculaire av. Mounier 73 B1.73.05 1200 Brussels – Belgium francoise.vanbambeke@uclouvain.be ABSTRACT (edited) Background: PA is the main cause of respiratory failure in cystic fibrosis (CF) patients. Its persistence in the lung is associated with its capacity to form biofilms, against which ABs are considered poorly active. We set up an in vitro model allowing for pharmacodynamic comparison of AB activity against PA biofilms grown in MHB or in ASM (mimicking the physicochemical conditions prevailing in CF patients' lungs). Methods: PAO1 and ATCC39324 (mucoid strain) were grown in MHB or ASM (see Table) in microplates for up to 12 days, with medium replacement every 48h. They were thereafter exposed to ABs during 24h, using a broad range of concentrations in order to obtain full concentration-response curves and calculate maximal efficacy (Emax) and relative potency (C50) by fitting a Hill equation (sigmoid) to the data. Biofilm biomass and bacterial viability within biofilms were quantified using crystal violet (CV) and fluorescein diacetate (PMID: 15567221) assays. In parallel, MBC were determined on planktonic cultures and in both media by CFU enumeration. Results: MBCs were 4-8 dilutions higher in ASM than in MHB except for MEM against the mucoïd strain. Supplementing MHB with mucin (CAZ, CST), DNA (CIP, AMK) or egg yolk (MEM) increased MBCs to the values observed in ASM. Stronger biofilms were produced in ASM and for the mucoid strain (CV absorbance at day 12: approx. 2 and 4 for PAO1 and 6 and 10 for ATCC39324 in MHB and ASM respectively). In most cases, ABs were less effective (lower Emax) and less potent (higher C50) (i) on biomass than on viability and (ii) in ASM than in MHB (except CIP, AMK, MEM [PAO1 only] equipotent for viability in both media). CIP, AMK and MEM (PAO1 only) were globally the most effective and potent drugs in both media but still remained unable to eradicate bacteria within biofilms (figure 4). Conclusions: In this model, CIP, AMK and to some extent MEM appear the most active on PA biofilms. ASM constituents reduce bactericidal activity, which may contribute to explain biofilm persistence in CF patients. INTRODUCTION P. aeruginosa is an opportunistic pathogen involved in many chronic infections. In cystic fibrosis patients, it persists in the lung as biofilms, in which bacteria are embedded in a matrix and protected from the host immune system. In these biofilms, P. aeruginosa adopts specific phenotypes (metabolically less active, sessile or mucoïd [overproducing exopolysaccharides as alginate]) [1], which are much less responsive to antibiotic activity than planktonic bacteria. To investigate the activity of commonly used antipseudomonal antibiotics against such biofilms, we developed an in vitro biofilm model in an Artificial Sputum Medium (ASM) mimicking the physico-chemical properties of the mucus of cystic fibrosis patients (2). RESULTS Antibiotic activity on metabolic activity and biomass in mature biofilms Table 1: MIC/MBC against PAO1 and ATCC 39324 in standard medium and ASM MICs were similar or higher in ASM as compared to MHB MBCs were markedly higher in ASM than in MHB Table 2: Antibiotic interactions with ASM components Table 3: Concentrations (in mg/L) causing 50 % reduction in metabolic activity within biofilms (C50) AIMS OF THE STUDY To compare the activity of antibiotics against biofilms grown in broth or in ASM. To test for the specific influence of ASM components on the intrinsic activity of antibiotics. To iInvestigate the importance of P. aeruginosa phenotype on antibiotic activity. METHODS Strains: reference PAO1 and stable mucoïd ATCC30324 Media: Mueller Hinton Broth (MHB); Artificial Sputum Medium (ASM) [2]. ASM (1L): mucin 10g, DNA 4g, diethylene triamine pentaacetic acid 5.9mg, casaminoacids 5g, NaCl 4g, KCl 2.2g, tris base 1.81g, egg yolk emulsion 5mL. MICs were determined by microdilutions according to CLSI recommendations; MBCs were determined as the concentration for which ≥99.9% reduction of the initial inoculum was observed after plating on Tryptic Soy Agar plates. Biofilms were grown for up to 12 days in 96 well plates and then exposed for 24h to antibiotics. Quantification of biofilms was obtained by measurement of biomass via crystal violet staining and viability by fluorescein diacetate assay (FDA) [3] Crystal violet (CV) Fluorescein diacetate (FDA) Mucin, DNA and egg yolk contributed to decrease bactericidal activity. In most of the cases, antibiotic relative potency against viability within biofilms was reduced (higher C50) in ASM. CONCLUSIONS Antibiotic potency against P. aeruginosa growing in biofilms is markedly reduced in artificial sputum medium, possibly due to interactions with specific constituents which impair bactericidal activity. Poor bacterial responsiveness in these conditions may contribute to explain persistence of infection in cystic fibrosis patients. These data emphasize the importance of selecting appropriate media for testing antibiotic activity in vitro in order to get clinically-meaningful conclusions. REFERENCES Ciofu et al. Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections. FEMS Immunol Med Microbiol. 2012; 65:215-25 (2) Sriramulu et al. Microcolony formation: a novel model of Pseudomonas aeruginosa for the cystic fibrosis lung. J Med Microbiol. 2005; 54 (Pt7):667-76 (3) Wanandy et al. Optimisation of the fluorescein diacetate assay. J Microbiol Methods 2005; 60: 21-30 In most of the cases, activity was similar against bacterial viability and biomass. Antibiotics were less active in ASM compared to the standard medium (lower potencies [higher C50; see C50 in Table 3] and lower maximal efficacies against the mucoid strains for some drugs). None of the tested antibiotics was able to completely eradicate mature biofilms. Crystal violet binds to negatively charged surface molecules and to polysaccharides in the extracellular matrix. It stains living and dead bacteria as well as the matrix allowing the quantification of the biofilm biomass. The quantification of biofilm viability was based on bacterial ability to convert non-fluorescent fluorescein diacetate into highly fluorescent fluorescein by non-specific esterases. This poster will be made available for download after the meeting at : http://www.facm.ucl.ac.be/posters